Research shows TensGuard from Dutch firm DSM is effective under pressure

A recent clinical trial conducted by TNO, a leading independent Dutch research organization, shows that Netherlands-based life science firm DSM's breakthrough dairy peptide ingredient, TensGuard, successfully lowers systolic and diastolic blood pressure in people with mild hypertension. These results will be welcome news for functional food and dietary supplement manufacturers looking for effective ingredients to tap into the growing market for blood pressure management products, says the company.

The study was a randomized, placebo-controlled, double-blind crossover trial involving 80 subjects all aged between 30 and 70. All participants were pre-hypertensive or at stage 1 hypertension at the start of the trial, as assessed at pre-study screenings. The subjects were all given a course of capsules containing either TensGuard or a placebo. They consumed two of these daily for a period of four weeks - one after breakfast and one after the evening meal.

The results demonstrate that TensGuard has a beneficial effect on blood pressure levels. The subjects with stage 1 hypertension saw a reduction in blood pressure following treatment with TensGuard, compared with the placebo. Systolic blood pressure was shown to reduce by 3.8mmHg and diastolic blood pressure by 2.3mmHg. Research studies indicate that a reduction in systolic blood pressure of 3-5 mmHg is associated with a decrease in the risk for stroke and coronary heart disease of approximately 15% and 10% respectively.